PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Perihilar Cholangiocarcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Contact: Study coordinator (Rui Zhang, PhD) · zhangr95@mail.sysu.edu.cn · 020-34078840

Study leads

Chao Liu, PhD
Principal Investigator
Department of Biliary and Pancreatic Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

Cholangiocarcinoma · Hilar Cholangiocarcinoma · Bile Duct Cancer

Abroad (travel likely)RecruitingPHASE2

Jinan, China

Endobiliary Radiofrequency Ablation for Malignant Biliary Obstruction Due to Perihilar Cholangiocarcinoma

Perihilar Cholangiocarcinoma

Abroad (travel likely)Recruiting

Amsterdam, Netherlands

LIver TrAnspLantation for Non-resectable Peri-HIlar cholangioCArcinoma (LITALHICA)

Perihilar Cholangiocarcinoma

Abroad (travel likely)Recruiting

Padova, Italy

A Cell-free DNA Methylation Blood-Based Test for Biliary Tract Cancers Screening

Gall Bladder Cancer · Intrahepatic Cholangiocarcinoma (Icc) · Extrahepatic Cholangiocarcinoma

Abroad (travel likely)Recruiting

Shanghai, China